Sunday 17 March 9 sessions
Monday 18 March 9 sessions
Tuesday 19 March 9 sessions
Wednesday 20 March 10 sessions
Theresa Selth
Theresa Selth
Sun 17 13:15 Breast and prostate cancer - more similar than different
Breast and prostate cancer - more similar than different
Janet Stanford
Janet Stanford
Sun 17 13:30 Session I: Breast and prostate cancer - more similar than different
Genetic susceptibility and risk stratification for prostate cancer screening and prevention
Oscar Rueda
Oscar Rueda
Sun 17 13:30 Session I: Breast and prostate cancer - more similar than different
Statistical approaches to personalised medicine in breast cancer
Felix Feng
Felix Feng
Sun 17 13:30 Session I: Breast and prostate cancer - more similar than different
Basal vs luminal molecular subtyping in breast and prostate cancer: Implications for treatment selection
Adrian Lee
Adrian Lee
Sun 17 13:30 Session I: Breast and prostate cancer - more similar than different
Overcoming inter-patient heterogeneity – intra-patient analysis of breast cancer evolution
Steffi Osterreich
Steffi Osterreich
Sun 17 15:20 Session II: Estrogen and androgen receptors: still key drivers?
Estrogen receptor alterations - the most frequent cause of death from breast cancer?
Ganesh Raj
Ganesh Raj
Sun 17 15:20 Session II: Estrogen and androgen receptors: still key drivers?
Overcoming endocrine resistance: masterminds, metaphors and mutants
Theresa Hickey
Theresa Hickey
Sun 17 15:20 Session II: Estrogen and androgen receptors: still key drivers?
When is AR oncogenic in breast cancer?
Steve Balk
Steve Balk
Sun 17 15:20 Session II: Estrogen and androgen receptors: still key drivers?
Persistent AR activity in enzalutamide resistant prostate cancer?
Geof Greene
Geof Greene
Sun 17 15:20 Session II: Estrogen and androgen receptors: still key drivers?
Unexpected therapeutic efficacy of a SERM in mutant ER breast cancer
Liz Caldon
Liz Caldon
Sun 17 17:00 Flash talks
Mechanisms underlying uncontrolled genome doubling in breast cancer
Liz Caldon
Liz Caldon
Wed 20 15:00 Inaugural “Rob Sutherland Award”
Mechanisms underlying uncontrolled genome doubling in breast cancer
Aurélie Cazet
Aurélie Cazet
Sun 17 17:00 Flash talks
Targeting stromal remodelling and cancer stem cell plasticity overcomes chemoresistance in metastatic triple negative breast cancer
Sara Charmsaz
Sara Charmsaz
Sun 17 17:00 Flash talks
Epi-transcriptomic alterations in ER-positive breast cancer
Liesel FitzGerald
Liesel FitzGerald
Sun 17 17:00 Flash talks
Array comparative genomic hybridisation of familial prostate cancer tumours identifies a recurrent copy number gain on chr19p13.3 encompassing the EEF2 gene
Luc Furic
Luc Furic
Sun 17 17:00 Flash talks
Estrogen receptor alpha controls gene expression via translational offsetting
Mitchell Lawrence
Mitchell Lawrence
Sun 17 17:00 Flash talks
New combination therapies for castration-resistant prostate cancer
Amy McCart-Reed
Amy McCart-Reed
Sun 17 17:00 Flash talks
LobSig, a prognostic signature for ILC 22
Sam Oakes
Sam Oakes
Sun 17 17:00 Flash talks
Flicking the switch off, targeting MCL-1 in the treatment of breast and prostate cancer
Cameron Snell
Cameron Snell
Sun 17 17:00 Flash talks
Exploring the clinical significance of interactions between oestrogen and progesterone receptors in breast and endometrioid adenocarcinomas by proximity ligation assay
Rinath Jeselsohn
Rinath Jeselsohn
Mon 18 08:30 Session III: Endocrine resistance – common mechanisms?
Endocrine resistance: The most common clinical mechanism
Luca Magnani
Luca Magnani
Mon 18 08:30 Session III: Endocrine resistance – common mechanisms?
Endocrine resistance – common mechanisms? Not really. To each its own, a single cell tale of resistance
Scott Dehm
Scott Dehm
Mon 18 08:30 Session III: Endocrine resistance – common mechanisms?
Endocrine uncoupling: When androgen receptors are no longer receptors
Manav Korpal
Manav Korpal
Mon 18 08:30 Session III: Endocrine resistance – common mechanisms?
Discovery and development of a first-in-class oral selective ERα covalent antagonist (SERCA) for the treatment of ERαWT/MUTb breast cancer
Housheng He
Housheng He
Mon 18 10:30 Session IV: Other ‘omics
Transcriptomic and functional landscape of circular RNA in prostate and breast cancer
Gavin Ha
Gavin Ha
Mon 18 10:30 Session IV: Other ‘omics
Profiling whole cancer genomes from circulating tumor DNA
Wilbert Zwart
Wilbert Zwart
Mon 18 10:30 Session IV: Other ‘omics
Cistromics in clinical trials: Mechanistic insights in tumorigenesis and disease progression?
Alex Swarbrick
Alex Swarbrick
Mon 18 10:30 Session IV: Other ‘omics
Multi-dimensional single cell analysis of the tumour microenvironment
Leigh Ellis
Leigh Ellis
Mon 18 13:10 Session V: Cell plasticity and tumorigenesis
Exploiting RB1 deficiency for novel therapeutic targets in prostate cancer
Amina Zoubeidi
Amina Zoubeidi
Mon 18 13:10 Session V: Cell plasticity and tumorigenesis
Cell plasticity in treatment resistant prostate cancer
Natasha Kyprianou
Natasha Kyprianou
Mon 18 13:10 Session V: Cell plasticity and tumorigenesis
Androgen interference with prostate cancer response to Cabazitaxel
Jane Visvader
Jane Visvader
Mon 18 13:10 Session V: Cell plasticity and tumorigenesis
Dissecting intraclonal plasticity during breast oncogenesis
Shahneen Sandhu
Shahneen Sandhu
Mon 18 15:20 Session VI: Harnessing the immune system
Immunotherapy in prostate cancer: challenges and progress
Anita Dunbier
Anita Dunbier
Mon 18 15:20 Session VI: Harnessing the immune system
Immune involvement and therapies in ER-positive breast cancer
Belinda Parker
Belinda Parker
Mon 18 15:20 Session VI: Harnessing the immune system
Reversing tumour invisibility in bone to combat metastatic disease
David Quinn
David Quinn
Mon 18 15:20 Session VI: Harnessing the immune system
Role of tumor blood vessels and response to check point inhibitors
Carlo Palmieri
Carlo Palmieri
Mon 18 15:20 Session VI: Harnessing the immune system
Immunotherapy for breast cancer: challenges and opportunities
Professor Charlotte Bevan
Charlotte Bevan
Tue 19 08:30 Session VII: Novel therapeutic targets
MicroRNAs: a potential new therapeutic avenue
Andrei Goga
Andrei Goga
Tue 19 08:30 Session VII: Novel therapeutic targets
New metabolic and mitotic targets in TNBC
Geoff Lindeman
Geoff Lindeman
Tue 19 08:30 Session VII: Novel therapeutic targets
Targeting cell survival pathways in breast cancer using BH3 mimetics
David Ortega
David Ortega
Tue 19 10:30 Session VIII: New instruments in the breast and prostate cancer symphony
A novel biomimetic tissue engineering platform to understand molecular mechanisms of drug resistance at single cell resolution
Richard Iggo
Richard Iggo
Tue 19 10:30 Session VIII: New instruments in the breast and prostate cancer symphony
What I cannot create, I do not understand: are MIND models the answer?
Violeta Serra
Violeta Serra
Tue 19 10:30 Session VIII: New instruments in the breast and prostate cancer symphony
Challenges and opportunities using ER-positive patient-derived tumour xenoimplant models
Dietmar Hutmacher
Dietmar Hutmacher
Tue 19 10:30 Session VIII: New instruments in the breast and prostate cancer symphony
Convergence of regenerative medicine principles to develop new breast and prostate cancer mice models
Frank Claessens
Frank Claessens
Wed 20 08:30 Session IX: Nuclear receptors and co-regulators: What’s new?
Live from an androgen receptor lab: some old news revisited
Carol Sartorius
Carol Sartorius
Wed 20 08:30 Session IX: Nuclear receptors and co-regulators: What’s new?
PR-RAR crosstalk in breast cancer
Richard Pestell
Richard Pestell
Wed 20 08:30 Session IX: Nuclear receptors and co-regulators: What’s new?
DACH1 gene deletion extends portraits of human prostate cancer
Patricia Elizalde
Patricia Elizalde
Wed 20 08:30 Session IX: Nuclear receptors and co-regulators: What’s new?
My name is ErbB-2, I will be called a transcription factor
Ian Mills
Ian Mills
Wed 20 10:30 Session X: Cellular homeostasis
Contributions of the unfolded protein response and glycosylation to homeostasis
David Thomas
David Thomas
Wed 20 10:30 Session X: Cellular homeostasis
Aggressive cancer homeostasis through dynamic flux
Lisa Butler
Lisa Butler
Wed 20 10:30 Session X: Cellular homeostasis
Membrane lipid remodelling: untapped opportunities to predict and disrupt metastasis of hormone-dependent cancers
Vincent Giguère
Vincent Giguère
Wed 20 10:30 Session X: Cellular homeostasis
The AR/mTOR/DNA-PK nuclear complexes: the missing links in prostate cancer?
Donald McDonnell
Donald McDonnell
Wed 20 10:30 Session X: Cellular homeostasis
Dyslipidemia and breast cancer pathobiology
Leonie Young
Leonie Young
Wed 20 13:15 Session XI: Building a rabbit proof fence: the tumour “terroir”
Understanding the transcriptomic circulatory – blocking the rabbit holes early
Pete Nelson
Pete Nelson
Wed 20 13:15 Session XI: Building a rabbit proof fence: the tumour “terroir”
Intrinsic and extrinsic drivers of micro- and macro-metastasis
Jason Lee
Jason Lee
Wed 20 13:15 Session XI: Building a rabbit proof fence: the tumour “terroir”
Harnessing the epigenome: a handbrake for metastasis
Christine Chaffer
Christine Chaffer
Wed 20 13:15 Session XI: Building a rabbit proof fence: the tumour “terroir”
Cancer cell plasticity drives the development of chemoresistance in breast cancer
Jyotsna Batra
Jyotsna Batra
Wed 20 15:00 Inaugural “Rob Sutherland Award”
A GWAS identified functional variation in PSA (KLK3) gene that confers lower risk is also associated with more aggressive disease and lower survival in men with prostate cancer
Kara Britt
Kara Britt
Wed 20 15:00 Inaugural “Rob Sutherland Award”
Estrogen receptor positive luminal progenitors the cancer cell of origin for estrogen receptor positive breast cancer
Melissa Davis
Melissa Davis
Wed 20 15:00 Inaugural “Rob Sutherland Award”
Combinatorial co-targeting by miRNAs: a subtle but strong regulator of epithelial-mesenchymal transitions
Phil Gregory
Phil Gregory
Wed 20 15:00 Inaugural “Rob Sutherland Award”
Estrogen receptor regulated miR-342 suppresses a pro-metastatic gene network
Luke Selth
Luke Selth
Wed 20 15:00 Inaugural “Rob Sutherland Award”
A miR-194-regulated transcriptional network is associated with progression to androgen receptor-independent prostate cancer
Rasmus Siersbaek
Rasmus Siersbaek
Wed 20 15:00 Inaugural “Rob Sutherland Award”
IL6/STAT3 co-opts ER regulatory elements to drive metastasis in breast cancer
Jason Carroll
Jason Carroll
Wed 20 08:30 Session IX: Nuclear receptors and co-regulators: What’s new?
How many associated proteins? What ones are important?
Simak Ali
Simak Ali
Tue 19 08:30 Session VII: Novel therapeutic targets
Therapeutic targeting of gene regulatory processes in breast cancer
Sun 17
11:00 - 13:00 
Registration and poster set-up
Sun 17
13:00 - 13:15 
Welcome - Wayne Tilley (DRMCRL, University of Adelaide, Adelaide)
Sun 17
13:15 - 13:30 
Breast and prostate cancer - more similar than different
13:15
Breast and prostate cancer - more similar than different
Theresa Selth (DRMCRL, Adelaide)
Sun 17
13:30 - 15:00 
Session I: Breast and prostate cancer - more similar than different
Chairs: Vanessa Hayes (Garvan Institute of Medical Research, Sydney) & Ed Gelmann (Columbia University, New York)
Genetic susceptibility and risk stratification for prostate cancer screening and prevention
Janet Stanford (Fred Hutchinson Cancer Research Centre, Seattle)
Statistical approaches to personalised medicine in breast cancer
Oscar Rueda (CRUK, Cambridge)
Basal vs luminal molecular subtyping in breast and prostate cancer: Implications for treatment selection
Felix Feng (University of California, San Francisco)
Overcoming inter-patient heterogeneity – intra-patient analysis of breast cancer evolution
Adrian Lee (UPMC, Pittsburgh)
General discussion (40–45 minutes)
Sun 17
15:00 - 15:20 
Break
Sun 17
15:20 - 16:50 
Session II: Estrogen and androgen receptors: still key drivers?
Chairs: Gail Risbridger (Monash University, Melbourne) & Elgene Lim (Garvan Institute of Medical Research, Sydney)
Estrogen receptor alterations - the most frequent cause of death from breast cancer?
Steffi Osterreich (University of Pittsburgh, Pittsburgh)
Overcoming endocrine resistance: masterminds, metaphors and mutants
Ganesh Raj (UT Southwestern Medical Centre, Dallas)
When is AR oncogenic in breast cancer?
Theresa Hickey (DRMCRL, Adelaide)
Persistent AR activity in enzalutamide resistant prostate cancer?
Steve Balk (Beth Israel Deaconess Medical Center, Boston)
Unexpected therapeutic efficacy of a SERM in mutant ER breast cancer
Geof Greene (University of Chicago, Chicago)
General discussion (40–45 minutes)
Sun 17
17:00 - 17:55 
Flash talks
Chairs: Renea Taylor (Monash University, Melbourne) & Colleen Nelson (Translational Research Institute/QUT, Brisbane)
Mechanisms underlying uncontrolled genome doubling in breast cancer
Liz Caldon (Garvan Institute of Medical Research, Sydney)
Targeting stromal remodelling and cancer stem cell plasticity overcomes chemoresistance in metastatic triple negative breast cancer
Aurélie Cazet (Garvan Institute of Medical Research, Sydney)
Epi-transcriptomic alterations in ER-positive breast cancer
Sara Charmsaz (Royal College of Surgeons in Ireland, Dublin)
Array comparative genomic hybridisation of familial prostate cancer tumours identifies a recurrent copy number gain on chr19p13.3 encompassing the EEF2 gene
Liesel FitzGerald (Menzies Institute for Medical Research, Hobart)
Estrogen receptor alpha controls gene expression via translational offsetting
Luc Furic (Peter MacCallum Cancer Centre, Melbourne)
New combination therapies for castration-resistant prostate cancer
Mitchell Lawrence (Monash University, Melbourne)
LobSig, a prognostic signature for ILC 22
Amy McCart-Reed (UQ Centre for Clinical Research, Brisbane)
Flicking the switch off, targeting MCL-1 in the treatment of breast and prostate cancer
Sam Oakes (Garvan Institute of Medical Research, Sydney)
Exploring the clinical significance of interactions between oestrogen and progesterone receptors in breast and endometrioid adenocarcinomas by proximity ligation assay
Cameron Snell (Mater Research Institute, Brisbane)
Sun 17
18:00 - 18:45 
“Ron Ross Award” Oration – Dr Funmi Olopade, MD, University of Chicago Medicine, Chicago
Chairs: Wayne Tilley & Elgene Lim
Sun 17
19:15 - 23:00 
Welcome reception
Mon 18
07:00 - 08:30 
Breakfast
Mon 18
08:30 - 10:00 
Session III: Endocrine resistance – common mechanisms?
Chairs: Suzanne Fuqua (Baylor College of Medicine, Houston) & David Waugh (Queensland University of Technology, Brisbane)
Endocrine resistance: The most common clinical mechanism
Rinath Jeselsohn (Dana Farber Cancer Institute, Boston)
Endocrine resistance – common mechanisms? Not really. To each its own, a single cell tale of resistance
Luca Magnani (Imperial College London, London)
Endocrine uncoupling: When androgen receptors are no longer receptors
Scott Dehm (University of Minnesota, Minneapolis)
Discovery and development of a first-in-class oral selective ERα covalent antagonist (SERCA) for the treatment of ERαWT/MUTb breast cancer
Manav Korpal (H3 Biomedicine Inc, Cambridge MA)
General discussion (40–45 minutes)
Mon 18
10:00 - 10:30 
Break
Mon 18
10:30 - 12:00 
Session IV: Other ‘omics
Chairs: Gail Prins (University of Illinois, Chicago) & Chris Ormandy (Garvan Institute of Medical Research, Sydney)
Transcriptomic and functional landscape of circular RNA in prostate and breast cancer
Housheng He (University of Toronto, Toronto)
Profiling whole cancer genomes from circulating tumor DNA
Gavin Ha (Fred Hutchinson Cancer Research Centre, Seattle)
Cistromics in clinical trials: Mechanistic insights in tumorigenesis and disease progression?
Wilbert Zwart (Netherlands Cancer Institute, Amsterdam)
Multi-dimensional single cell analysis of the tumour microenvironment
Alex Swarbrick (Garvan Institute of Medical Research, Sydney)
General discussion (40–45 minutes)
Mon 18
12:00 - 13:10 
Lunch
Mon 18
13:10 - 14:40 
Session V: Cell plasticity and tumorigenesis
Chairs: Judith Clements (Queensland University of Technology, Brisbane) & Greg Goodall (Centre for Cancer Biology, University of South Australia, Adelaide)
Exploiting RB1 deficiency for novel therapeutic targets in prostate cancer
Leigh Ellis (Dana Farber Cancer Institute, Boston)
Cell plasticity in treatment resistant prostate cancer
Amina Zoubeidi (University of British Columbia, Vancouver)
Androgen interference with prostate cancer response to Cabazitaxel
Natasha Kyprianou (University of Kentucky, Lexington)
Dissecting intraclonal plasticity during breast oncogenesis
Jane Visvader (Walter and Eliza Hall Institute, Melbourne)
General discussion (40–45 minutes)
Mon 18
15:00 - 15:20 
Break
Mon 18
15:20 - 16:50 
Session VI: Harnessing the immune system
Chairs: Mike Brown (Royal Adelaide Hospital, Adelaide) & Anthony Joshua (Kinghorn Cancer Centre, Sydney)
Immunotherapy in prostate cancer: challenges and progress
Shahneen Sandhu (Peter MacCallum Cancer Centre, Melbourne)
Immune involvement and therapies in ER-positive breast cancer
Anita Dunbier (University of Otago, Dunedin)
Reversing tumour invisibility in bone to combat metastatic disease
Belinda Parker (La Trobe Institute for Molecular Science, Melbourne)
Role of tumor blood vessels and response to check point inhibitors
David Quinn (USC Norris Comprehensive Cancer Center, Los Angeles)
Immunotherapy for breast cancer: challenges and opportunities
Carlo Palmieri (University of Liverpool, Liverpool)
General discussion (40–45 minutes)
Mon 18
19:00 - 23:00 
Dinner
Tue 19
07:00 - 08:30 
Breakfast
Tue 19
08:30 - 10:00 
Session VII: Novel therapeutic targets
Chairs: Carlo Palmieri (University of Liverpool, Liverpool) & Chris Sweeney (Dana Farber Cancer Institute, Boston)
MicroRNAs: a potential new therapeutic avenue
Charlotte Bevan (London, UK)
New metabolic and mitotic targets in TNBC
Andrei Goga (University of California, San Francisco)
Therapeutic targeting of gene regulatory processes in breast cancer
Simak Ali
Targeting cell survival pathways in breast cancer using BH3 mimetics
Geoff Lindeman (Walter and Eliza Hall Institute, Melbourne)
General discussion (40–45 minutes)
Tue 19
10:00 - 10:30 
Break
Tue 19
10:30 - 12:00 
Session VIII: New instruments in the breast and prostate cancer symphony
Chairs: Eva Corey (University of Washington, Seattle) & Stephen Birrell (University of Adelaide, Adelaide)
A novel biomimetic tissue engineering platform to understand molecular mechanisms of drug resistance at single cell resolution
David Ortega (Garvan Institute of Medical Research, Sydney)
What I cannot create, I do not understand: are MIND models the answer?
Richard Iggo (University of Bordeaux, Bordeaux)
Challenges and opportunities using ER-positive patient-derived tumour xenoimplant models
Violeta Serra (VHIO - Vall Hebron Institute of Oncology, Barcelona)
Convergence of regenerative medicine principles to develop new breast and prostate cancer mice models
Dietmar Hutmacher (Institute of Health and Biomedical Innovation QUT, Brisbane)
General discussion (40–45 minutes)
Tue 19
12:00 - 13:00 
Lunch
Tue 19
13:00 - 16:30 
Free time
Tue 19
16:30 - 18:30 
Poster session
Tue 19
19:00 - 23:00 
Dinner
Tue 19
20:15 - 21:30 
The Great Debate – “Are humans the only model?”
Moderator: Chris Sweeney. For: Alex Swarbrick (Team Captain), Melissa Davis, Scott Dehm, Luca Magnani, Steffi Oesterreich, Amina Zoubeidi. Against: Carol Lange (Team Captain), Charlotte Bevan, Steve Birrell, Donald McDonnell, Sam Oakes, Wilbert Zwart. Judges: Suzanne Fuqua, Geof Greene, Gail Prins, Gail Risbridger
Wed 20
07:00 - 08:30 
Breakfast
Wed 20
08:30 - 10:00 
Session IX: Nuclear receptors and co-regulators: What’s new?
Chairs: Carol Lange (University of Minnesota, Minneapolis) & Robert Matusik (Vanderbilt University Medical Centre, Nashville)
How many associated proteins? What ones are important?
Jason Carroll
Live from an androgen receptor lab: some old news revisited
Frank Claessens (KU Leuven University, Leuven)
PR-RAR crosstalk in breast cancer
Carol Sartorius (University of Colorado, Denver)
DACH1 gene deletion extends portraits of human prostate cancer
Richard Pestell (Baruch S Blumberg Institute, Philadelphia)
My name is ErbB-2, I will be called a transcription factor
Patricia Elizalde (Institut de Biologica y Medicina Experimental, Buenos Aires)
General discussion (40–45 minutes)
Wed 20
10:00 - 10:30 
Break
Wed 20
10:30 - 12:00 
Session X: Cellular homeostasis
Chairs: Sam Oakes (Garvan Institute of Medical Research, Sydney) & Jeff Holst (University of New South Wales, Sydney)
Contributions of the unfolded protein response and glycosylation to homeostasis
Ian Mills (Oxford University / Queen's University of Belfast, Oxford)
Aggressive cancer homeostasis through dynamic flux
David Thomas (Broad Institute, Boston)
Membrane lipid remodelling: untapped opportunities to predict and disrupt metastasis of hormone-dependent cancers
Lisa Butler (University of Adelaide / SAHMRI, Adelaide)
The AR/mTOR/DNA-PK nuclear complexes: the missing links in prostate cancer?
Vincent Giguère (McGill University, Montreal)
Dyslipidemia and breast cancer pathobiology
Donald McDonnell (Duke University School of Medicine, Durham)
General discussion (40–45 minutes)
Wed 20
12:00 - 13:15 
Lunch
Wed 20
13:15 - 14:45 
Session XI: Building a rabbit proof fence: the tumour “terroir”
Chairs: Robin Anderson (Olivia Newton-John Cancer Research Centre, Melbourne) & Rik Thompson (Queensland Uni of Technology, Brisbane)
Understanding the transcriptomic circulatory – blocking the rabbit holes early
Leonie Young (Royal College of Surgeons in Ireland, Dublin)
Intrinsic and extrinsic drivers of micro- and macro-metastasis
Pete Nelson (Fred Hutchinson Cancer Research Centre, Seattle)
Harnessing the epigenome: a handbrake for metastasis
Jason Lee (QIMR Berghofer, Brisbane)
Cancer cell plasticity drives the development of chemoresistance in breast cancer
Christine Chaffer (Garvan Institute of Medical Research, Sydney)
General discussion (40–45 minutes)
Wed 20
14:45 - 15:00 
Break
Wed 20
15:00 - 16:30 
Inaugural “Rob Sutherland Award”
Chairs: David Quinn (USC Norris Comprehensive Cancer Center, Los Angeles) & Lisa Horvath (Chris O'Brien Lifehouse, Sydney)
A GWAS identified functional variation in PSA (KLK3) gene that confers lower risk is also associated with more aggressive disease and lower survival in men with prostate cancer
Jyotsna Batra (IHBI, Brisbane)
Estrogen receptor positive luminal progenitors the cancer cell of origin for estrogen receptor positive breast cancer
Kara Britt (Peter MacCallum Cancer Centre, Melbourne)
Mechanisms underlying uncontrolled genome doubling in breast cancer
Liz Caldon (Garvan Institute of Medical Research, Sydney)
Combinatorial co-targeting by miRNAs: a subtle but strong regulator of epithelial-mesenchymal transitions
Melissa Davis (Walter and Eliza Hall Institute, Melbourne)
Estrogen receptor regulated miR-342 suppresses a pro-metastatic gene network
Phil Gregory (Centre for Cancer Biology, Adelaide)
A miR-194-regulated transcriptional network is associated with progression to androgen receptor-independent prostate cancer
Luke Selth (DRMCRL, Adelaide)
IL6/STAT3 co-opts ER regulatory elements to drive metastasis in breast cancer
Rasmus Siersbaek (CRUK, Cambridge)
Wed 20
16:30 - 17:00 
Meeting close
Wed 20
19:00 - 23:00 
Conference dinner

You can download or link to the programme in iCal format and link to it with your personal calendar e.g. Oulook or Google calendar.

Sometimes this is known as subscribing to to a web or internet calendar.

TIP: Try copying the link (instead of downloading) into your calendar application and your calendar should pick up any changes that are made to the progrmme.

iCalendar of programme

iCalendar by day

https://programme.bioscientifica.com/espe2018/2019-03-17.ics
https://programme.bioscientifica.com/espe2018/2019-03-18.ics
https://programme.bioscientifica.com/espe2018/2019-03-19.ics
https://programme.bioscientifica.com/espe2018/2019-03-20.ics

Looking for a view of the calendar...?

At-a-glance provides an overview of Find out more...